Like the company, management, and they keep executing. Valuation can make sense if long term they can keep the 25-35% growth and keep expenses within reason. Another hold and add on weakness. Problem is in the microcap space there are a lot of “cheap” companies with similar growth opportunities.
Like the company, management, and they keep executing. Valuation can make sense if long term they can keep the 25-35% growth and keep expenses within reason. Another hold and add on weakness. Problem is in the microcap space there are a lot of “cheap” companies with similar growth opportunities.
Any chance of an update on Biorem? Solid report.
Biorem tomorrow I hope.